



(43) International Publication Date
1 August 2013 (01.08.2013)

(10) International Publication Number
WO 2013/112804 A1

(51) International Patent Classification:

A61K 9/16 (2006.01) *C07D 405/12* (2006.01)
A61K 9/20 (2006.01) *C07D 405/14* (2006.01)
A61K 9/28 (2006.01) *A61K 31/443* (2006.01)
C07D 213/75 (2006.01)

(21) International Application Number:

PCT/US2013/023100

(22) International Filing Date:

25 January 2013 (25.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/590,479	25 January 2012 (25.01.2012)	US
61/651,218	24 May 2012 (24.05.2012)	US
61/691,898	22 August 2012 (22.08.2012)	US
61/708,691	2 October 2012 (02.10.2012)	US

(71) Applicant (for all designated States except US): **VERTEX PHARMACEUTICALS INCORPORATED** [US/US];
130 Waverly Street, Cambridge, MA 02138 (US).

(72) Inventor; and

(71) Applicant (for US only): **VERWIJIS, Marinus, Jacobus** [US/US]; 4 Carter Drive, Framingham, MA 01701 (US).

(74) Agent: **DiVerdi, Michael, J.**; Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D])[1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID

(57) Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2- difluorobenzo [d] [1,3] dioxol-5 -yl) cyclopropanecarboxamido)-3 -methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Processes of preparing pharmaceutical compositions comprising Compound 1 are also disclosed.



WO 2013/112804 A1